vs
Clearway Energy, Inc.（CWEN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Clearway Energy, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$310.0M vs $207.3M），Clearway Energy, Inc.净利率更高（-33.5% vs -62.0%，领先28.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 21.1%），Clearway Energy, Inc.自由现金流更多（$71.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 8.6%）
NRG能源是总部位于美国得克萨斯州休斯敦的能源企业，前身为后续更名为埃克西尔能源的北方州电力公司的批发业务板块，2000年独立运营。业务覆盖发电与电力零售，拥有天然气、煤炭、石油、核能、风电、公用事业级及分布式太阳能等发电资产，服务超700万零售用户。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CWEN vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $310.0M | $207.3M |
| 净利润 | $-104.0M | $-128.6M |
| 毛利率 | 51.9% | — |
| 营业利润率 | -11.9% | -54.7% |
| 净利率 | -33.5% | -62.0% |
| 营收同比 | 21.1% | 25.9% |
| 净利润同比 | -3566.7% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $310.0M | $207.3M | ||
| Q3 25 | $429.0M | $159.9M | ||
| Q2 25 | $392.0M | $166.5M | ||
| Q1 25 | $298.0M | $139.3M | ||
| Q4 24 | $256.0M | $164.6M | ||
| Q3 24 | $486.0M | $139.5M | ||
| Q2 24 | $366.0M | $147.0M | ||
| Q1 24 | $263.0M | $108.8M |
| Q4 25 | $-104.0M | $-128.6M | ||
| Q3 25 | $236.0M | $-180.4M | ||
| Q2 25 | $33.0M | $-115.0M | ||
| Q1 25 | $4.0M | $-151.1M | ||
| Q4 24 | $3.0M | $-133.2M | ||
| Q3 24 | $36.0M | $-133.5M | ||
| Q2 24 | $51.0M | $-131.6M | ||
| Q1 24 | $-2.0M | $-170.7M |
| Q4 25 | 51.9% | — | ||
| Q3 25 | 70.2% | — | ||
| Q2 25 | 66.6% | — | ||
| Q1 25 | 59.1% | — | ||
| Q4 24 | 52.0% | — | ||
| Q3 24 | 72.2% | — | ||
| Q2 24 | 68.0% | — | ||
| Q1 24 | 52.1% | — |
| Q4 25 | -11.9% | -54.7% | ||
| Q3 25 | 26.1% | -106.9% | ||
| Q2 25 | 21.7% | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | -14.5% | -74.3% | ||
| Q3 24 | 36.6% | -94.6% | ||
| Q2 24 | 23.0% | -79.1% | ||
| Q1 24 | -11.0% | -151.9% |
| Q4 25 | -33.5% | -62.0% | ||
| Q3 25 | 55.0% | -112.8% | ||
| Q2 25 | 8.4% | -69.0% | ||
| Q1 25 | 1.3% | -108.5% | ||
| Q4 24 | 1.2% | -80.9% | ||
| Q3 24 | 7.4% | -95.7% | ||
| Q2 24 | 13.9% | -89.5% | ||
| Q1 24 | -0.8% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $231.0M | $421.0M |
| 总债务越低越好 | $7.9B | — |
| 股东权益账面价值 | $5.8B | $-80.0M |
| 总资产 | $16.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.36× | — |
8季度趋势，按日历期对齐
| Q4 25 | $231.0M | $421.0M | ||
| Q3 25 | $251.0M | $202.5M | ||
| Q2 25 | $260.0M | $176.3M | ||
| Q1 25 | $297.0M | $127.1M | ||
| Q4 24 | $332.0M | $174.0M | ||
| Q3 24 | $292.0M | $150.6M | ||
| Q2 24 | $226.0M | $480.7M | ||
| Q1 24 | $478.0M | $112.3M |
| Q4 25 | $7.9B | — | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $8.3B | — | ||
| Q1 25 | $7.2B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $6.8B | — | ||
| Q1 24 | $7.6B | — |
| Q4 25 | $5.8B | $-80.0M | ||
| Q3 25 | $5.7B | $9.2M | ||
| Q2 25 | $5.5B | $151.3M | ||
| Q1 25 | $5.4B | $144.2M | ||
| Q4 24 | $5.6B | $255.0M | ||
| Q3 24 | $5.6B | $346.8M | ||
| Q2 24 | $5.7B | $432.4M | ||
| Q1 24 | $5.0B | $140.3M |
| Q4 25 | $16.7B | $1.5B | ||
| Q3 25 | $16.1B | $1.2B | ||
| Q2 25 | $16.0B | $1.3B | ||
| Q1 25 | $14.6B | $1.3B | ||
| Q4 24 | $14.3B | $1.5B | ||
| Q3 24 | $14.2B | $1.5B | ||
| Q2 24 | $14.5B | $1.6B | ||
| Q1 24 | $14.9B | $1.3B |
| Q4 25 | 1.36× | — | ||
| Q3 25 | 1.41× | — | ||
| Q2 25 | 1.49× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 1.21× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | 1.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $177.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $71.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 22.9% | -48.6% |
| 资本支出强度资本支出/营收 | 34.2% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $369.0M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $177.0M | $-99.8M | ||
| Q3 25 | $225.0M | $-91.4M | ||
| Q2 25 | $191.0M | $-108.3M | ||
| Q1 25 | $95.0M | $-166.5M | ||
| Q4 24 | $192.0M | $-79.3M | ||
| Q3 24 | $301.0M | $-67.0M | ||
| Q2 24 | $196.0M | $-77.0M | ||
| Q1 24 | $81.0M | $-190.7M |
| Q4 25 | $71.0M | $-100.8M | ||
| Q3 25 | $144.0M | $-92.7M | ||
| Q2 25 | $115.0M | $-110.7M | ||
| Q1 25 | $39.0M | $-167.8M | ||
| Q4 24 | $142.0M | $-79.5M | ||
| Q3 24 | $266.0M | $-68.6M | ||
| Q2 24 | $92.0M | $-79.0M | ||
| Q1 24 | $-17.0M | $-193.9M |
| Q4 25 | 22.9% | -48.6% | ||
| Q3 25 | 33.6% | -58.0% | ||
| Q2 25 | 29.3% | -66.5% | ||
| Q1 25 | 13.1% | -120.5% | ||
| Q4 24 | 55.5% | -48.3% | ||
| Q3 24 | 54.7% | -49.2% | ||
| Q2 24 | 25.1% | -53.7% | ||
| Q1 24 | -6.5% | -178.2% |
| Q4 25 | 34.2% | 0.5% | ||
| Q3 25 | 18.9% | 0.8% | ||
| Q2 25 | 19.4% | 1.5% | ||
| Q1 25 | 18.8% | 1.0% | ||
| Q4 24 | 19.5% | 0.1% | ||
| Q3 24 | 7.2% | 1.2% | ||
| Q2 24 | 28.4% | 1.4% | ||
| Q1 24 | 37.3% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.95× | — | ||
| Q2 25 | 5.79× | — | ||
| Q1 25 | 23.75× | — | ||
| Q4 24 | 64.00× | — | ||
| Q3 24 | 8.36× | — | ||
| Q2 24 | 3.84× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CWEN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
